KR950031051A - 활성물질 및 케탈화 폴리타르트라미드산을 함유하는 나노입자, 이의 제조방법 및 용도 - Google Patents
활성물질 및 케탈화 폴리타르트라미드산을 함유하는 나노입자, 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- KR950031051A KR950031051A KR1019950004748A KR19950004748A KR950031051A KR 950031051 A KR950031051 A KR 950031051A KR 1019950004748 A KR1019950004748 A KR 1019950004748A KR 19950004748 A KR19950004748 A KR 19950004748A KR 950031051 A KR950031051 A KR 950031051A
- Authority
- KR
- South Korea
- Prior art keywords
- nanoparticles
- acid
- ketalized
- active substance
- polytartramide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
활성물질 및 케탈화 폴리타르트라미드산을 함유하는 나노입자는 활성물질, 특히 펩티드 및 단백질용 부형제로서 적당하다. 나노입자의 제조방법은 본 명세서에 상술되어 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 활성물질 및 하기 일반식(Ⅰ)으 반복구조단위 95mol% 이상을 함유하는 케탈화 폴리타르트라미드산을 함유하는 나노입자.상기식에서, R1은 구조식(Ⅱ)의 라디칼이고, X는 -NH-이고, R2는 하나 이상의 불활성 라디칼에 의해 치환될 수 있는 직쇄 또는 측쇄 알킬 또는 사이클로알킬이다.
- 제1항에 있어서, R1이 구조식(Ⅱ)의 화합물이고, X가 -NH-이고, R2가 a)탄소수 1내지 18의 직쇄 또는 측쇄의 알킬 또는 알케닐 또는 b) 1)카복실 또는 2)2.1 직쇄 또는 측쇄 -O-(C3-C18)-알킬, 2.2-O-(C3-C18)-사이클로알킬, 2.3 (C1-C6)-알킬아미노 또는 2.4 2. 4. 1 하이드록실 또는 2. 4. 2-O-(C2-C4)-알킬로 이루어진 그룹으로부터 선택된 라디칼에 의해 알킬 잔기가 1회 이상 치환된 (C1-C6)-알킬아미노로 이루어진 그룹으로부터의 라디칼에 의해 하이드록실 그룹이 치환된 카복실로 이루어진 그룹으로부터의 라디칼에 의해 1회 이 치환된 탄소수 1내지 18의 직쇄 또는 측쇄 또는 측쇄 알킬 또는 알케닐인 일반식(Ⅰ)의 케탈화 폴리타르트라미드산을 함유하는 나노입자.
- 제1항 또는 제2항에 있어서, R1이 구조식(Ⅱ)의 라디칼이고, X가 -NH-이고, R2가 a)탄소수 1내지 18의 알킬, b)(C3-C8)-사이클로알킬 또는 c)일반식[여기서, n은 3 또는 4이고 R6은 (C1-C18)-알콕시이다]의 라디칼인 일반식(Ⅰ)의 케탈화 폴리타르트라미드산을 함유하는 나노입자.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 직경이 10내지 1000㎚, 특히 200내지 600㎜인 나노입자.
- 제1항 내지 제4항 중의 어느 한 항에 있어서, 케탈화 폴리타르트라미드산에 대한 활성물질의 함량이 1내지 60%인 나노입자.
- 제1항 내지 제5항 중의 어느 한 항에 있어서, 활성물질로서 인슐린, 칼시토닌 또는 부셀렐린을 함유하는 나노입자.
- 제1항 내지 제5항 중의 어느 한 항에 있어서, 비타민 B12, 비타민 B12유사체 및 렉틴으로 이루어진 그룹으로부터의 리간드가 결합되는 나노입자.
- 제7항에 있어서, 리간드가 폴리비닐아민, 폴라아스파르트산, 폴리리신 및 O-(N-석신이미딜)-N,N,N',N'-테트라메틸우로늄 테트라플루오로보레이트로 이루어진 그룹으로부터의 커플링 그룹을 통해 결합되는 나노입자.
- a)활성물질 및 제1항에 따른 일반식(Ⅰ)의 케탈화 폴리타르트라미드산을 용해시키고, 임의로는 다른 보조제를 별도로 용해시키고, 수득된 용액을 혼합하고, 혼합물을 외경이 0.2 내지 1.2㎜인 캐뉼러를 통해 침전제에 도입시키거나, b)활성물질 및 제1항에 따른 일반식(Ⅰ)의 케탈화 폴리타르트라미드산을 개별적으로 용해시키고, 임의로는 다른 보조제를 용해시키고, 수득된 용액을 혼합하여 비점도가 0.2 내지 3.5인 용액을 수득하고 이를 분무건조시키고, c)하나 이상의 리간드에 a)또는 b)에 의해 수득된 나노입자를 결합시키고, d)커플링 그룹을 통해 하나 이상의 리간드에 a) 또는 b)에 의해 수득된 나노입자를 연결시키고, e)공극크기가 0.2 내지 0.8㎛인 필터를 통해 a),b),c) 또는 d)에 의해 수득된 나노입자를 여과시킴을 포함하는 제1항에 청구된 나노입자의 제조방법.
- 활성물질의 함량을 조절할 수 있고 경구 투여되는 약제학적 제제의 제조를 위한 제1항 내지 제8항 중의 어느 한 항에서 청구된 나노입자의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4407898A DE4407898A1 (de) | 1994-03-09 | 1994-03-09 | Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben |
DEP4407898.6 | 1994-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950031051A true KR950031051A (ko) | 1995-12-18 |
Family
ID=6512297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950004748A KR950031051A (ko) | 1994-03-09 | 1995-03-09 | 활성물질 및 케탈화 폴리타르트라미드산을 함유하는 나노입자, 이의 제조방법 및 용도 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5674531A (ko) |
EP (1) | EP0671169A1 (ko) |
JP (1) | JPH07258114A (ko) |
KR (1) | KR950031051A (ko) |
AU (1) | AU685577B2 (ko) |
CA (1) | CA2144216A1 (ko) |
DE (1) | DE4407898A1 (ko) |
FI (1) | FI951053A (ko) |
HU (1) | HUT72033A (ko) |
IL (1) | IL112905A (ko) |
NO (1) | NO307422B1 (ko) |
NZ (1) | NZ270648A (ko) |
TW (1) | TW457096B (ko) |
ZA (1) | ZA951910B (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
AUPO888097A0 (en) * | 1997-08-29 | 1997-09-25 | Biotech Australia Pty Limited | Cross-linked particles |
DE19745950A1 (de) * | 1997-10-17 | 1999-04-22 | Dds Drug Delivery Service Ges | Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation |
DE19810965A1 (de) * | 1998-03-13 | 1999-09-16 | Aventis Res & Tech Gmbh & Co | Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
US20060280761A1 (en) * | 2002-03-11 | 2006-12-14 | Health Plus International, Inc. | Nanofluidized B-12 composition and process for treating pernicious anemia |
US7244784B2 (en) * | 2002-06-14 | 2007-07-17 | Rohm And Haas Company | Aqueous nanoparticle dispersions |
US7208145B2 (en) * | 2002-12-31 | 2007-04-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
CA2482240A1 (en) * | 2004-09-27 | 2006-03-27 | Claude Choquet | Body motion training and qualification system and method |
EP1812864A2 (en) * | 2004-10-07 | 2007-08-01 | Emory University | Multifunctional nanoparticles conjugates and their use |
FR2904219B1 (fr) * | 2006-07-28 | 2010-08-13 | Flamel Tech Sa | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
JP5691273B2 (ja) * | 2009-07-23 | 2015-04-01 | Jnc株式会社 | 液晶配向剤、液晶配向膜及び液晶表示素子 |
US11344859B2 (en) | 2019-11-27 | 2022-05-31 | Smartdyelivery Gmbh | Reactor for the preparation of a formulation |
DE102019218404A1 (de) * | 2019-11-27 | 2021-05-27 | Smartdyelivery Gmbh | Reaktor zur Herstellung einer Formulierung |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0514790A2 (de) * | 1991-05-24 | 1992-11-25 | Hoechst Aktiengesellschaft | Polykondensate, die Weinsäurederivate enthalten, Verfahren zu ihrer Herstellung und Verwendung derselben |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US6159502A (en) * | 1991-04-02 | 2000-12-12 | Biotech Australia Pty Ltd | Oral delivery systems for microparticles |
-
1994
- 1994-03-09 DE DE4407898A patent/DE4407898A1/de not_active Withdrawn
-
1995
- 1995-02-20 TW TW084101519A patent/TW457096B/zh active
- 1995-03-03 EP EP95103045A patent/EP0671169A1/de not_active Withdrawn
- 1995-03-07 FI FI951053A patent/FI951053A/fi unknown
- 1995-03-07 IL IL11290595A patent/IL112905A/xx not_active IP Right Cessation
- 1995-03-07 US US08/399,474 patent/US5674531A/en not_active Expired - Fee Related
- 1995-03-07 NZ NZ270648A patent/NZ270648A/en unknown
- 1995-03-08 CA CA002144216A patent/CA2144216A1/en not_active Abandoned
- 1995-03-08 NO NO950889A patent/NO307422B1/no not_active IP Right Cessation
- 1995-03-08 AU AU14701/95A patent/AU685577B2/en not_active Ceased
- 1995-03-08 ZA ZA951910A patent/ZA951910B/xx unknown
- 1995-03-08 JP JP7048006A patent/JPH07258114A/ja active Pending
- 1995-03-08 HU HU9500698A patent/HUT72033A/hu unknown
- 1995-03-09 KR KR1019950004748A patent/KR950031051A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0514790A2 (de) * | 1991-05-24 | 1992-11-25 | Hoechst Aktiengesellschaft | Polykondensate, die Weinsäurederivate enthalten, Verfahren zu ihrer Herstellung und Verwendung derselben |
Also Published As
Publication number | Publication date |
---|---|
NO307422B1 (no) | 2000-04-03 |
DE4407898A1 (de) | 1995-09-14 |
US5674531A (en) | 1997-10-07 |
AU685577B2 (en) | 1998-01-22 |
CA2144216A1 (en) | 1995-09-10 |
AU1470195A (en) | 1995-09-21 |
HU9500698D0 (en) | 1995-04-28 |
NO950889D0 (no) | 1995-03-08 |
FI951053A (fi) | 1995-09-10 |
JPH07258114A (ja) | 1995-10-09 |
FI951053A0 (fi) | 1995-03-07 |
ZA951910B (en) | 1995-11-13 |
IL112905A (en) | 2000-08-31 |
NO950889L (no) | 1995-09-11 |
HUT72033A (en) | 1996-03-28 |
NZ270648A (en) | 1995-09-26 |
TW457096B (en) | 2001-10-01 |
IL112905A0 (en) | 1995-06-29 |
EP0671169A1 (de) | 1995-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950031051A (ko) | 활성물질 및 케탈화 폴리타르트라미드산을 함유하는 나노입자, 이의 제조방법 및 용도 | |
DE69008346T3 (de) | Arzneistoffabgabe-zusammensetzungen. | |
RU2160099C2 (ru) | Липосомальная фармацевтическая композиция для внутривенного введения | |
NO982364D0 (no) | FremgangsmÕte for fremstilling av morfologisk anhetlige mikrokapsler, samt mikrokapsler fremstilt ved fremgangsmÕten | |
FR2608988B1 (fr) | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules | |
AU2004222439B2 (en) | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | |
EP0221041A3 (en) | Benzimidazole derivatives, process for their preparation and their pharmaceutical use | |
EP0265966A3 (en) | Super paramagnetic fluids and methods of making super paramagnetic fluids | |
EP0943614A3 (de) | Diaminobenzol-Derivate enthaltende Färbemittel sowie die Diaminobenzol-Derivate | |
DE3610330A1 (de) | Loesung eines arzneimittels, verfahren zu ihrer zubereitung und diese enthaltende pharmazeutische zubereitung | |
CA2073680C (en) | Liposome composition | |
FR2734481B1 (fr) | Pseudo-emulsions stabilisees et leur procede de preparation | |
EP0173664A3 (en) | Biologically active benzimidazole compounds and process for their preparation | |
EP0324347A3 (de) | Neue 3,5-Dihydroxycarbonsäuren und deren Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, pharmazeutische Präparate und Zwischenprodukte | |
EP0327709A3 (en) | Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use | |
KR910002899A (ko) | 혈조절 펩타이드 | |
JPH10330288A (ja) | 金属微粒子複合体及びこれを利用した造影剤 | |
FR2613223B1 (fr) | Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation | |
FR2650280B1 (fr) | (2r,cis)-1,2-epoxypropyl-phosphonate de mono-(2-ammonium-2-hydroxymethyl-1,3-propanediol) ayant des caracteristiques ameliorees de stabilite, son procede de preparation et compositions pharmaceutiques le contenant | |
KR910011266A (ko) | 유체형태의 경구투여용 약학적 제제 | |
JPS57149217A (en) | Slow-releasing pharmaceutical preparation | |
EP0354418A3 (de) | 6-Fluor-3,5-dihydroxycarbonsäuren und deren Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, pharmazeutische Präparate und Zwischenprodukte | |
RU2256440C2 (ru) | Фармацевтический препарат | |
Jonsson et al. | 6‐AMINODOPAMINE‐INDUCED DEGENERATION OF CATECHOLAMINE NEURONS | |
DE69016592D1 (de) | 4-Amidino-Chroman und 4-Amidino-Pyrano(3,2-c)pyridinderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |